Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

Abstract

In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.

Do Double-Expressor High-Grade B-Cell Lymphomas Really Need Intensified Treatment? A Report from the Real-Life Series of High-Grade B-Cell Lymphomas Treated with Different Therapeutic Protocols at the Institute of Oncology Ljubljana

“…Still, these data are based on younger and smaller series of patients [9,10]. Accordingly, limited reports have already been published comparing the R-CHOP and R-DA-EPOCH in the DEL patient population, among which is a study by Devi and colleagues [22] that included 113 patients and a multicentre study of 90 patients in the USA [23]. Both studies actually disclosed no differences in survival among the two protocols applied.…”

“Double expressor” diffuse large B-cell lymphoma: A case report and literature review

“…Notwithstanding, a small study from the same year [28] showed a favorable treatment outcome with R-EPOCH in comparison with R-CHOP in DEL DLBCL patients. In the following years, the number of researches that do not favor therapy intensification for patients with DEL [29][30][31] notably outnumbered those who do favor intensification [32]. Systematic review and meta-analysis by Hwang et al [33], that included 7054 patients from 41 studies, confirmed that CR rate is significantly lower in newly diagnosed DEL than non-DEL DLBCL patients.…”

Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital

“…Devi и соавт. [8] показали, что при медиане наблюдения 2 года медианы ОВ и ВБП в группе больных с ДВККЛ (DHL/THL), получавших терапию R-EPOCH, были аналогичны таковым в группе пациентов с этим же вариантом лимфопролиферативного заболевания, которым проводилось лечение в режиме R-CHOP, составив 13,8 мес против 14,2 мес и 10,5 мес против 10,6 мес соответственно. При этом авторы не отметили увеличения токсичности в случае применения режима R-EPOCH.…”